The Cosmetic Products Notification Portal (CPNP)
Only cosmetic products for which a legal or natural person is designated within the EU as a "Responsible Person" can be placed on the European Union (EU) market. Before placing a cosmetic product on the EU market, the RP must notify it in the Cosmetic Products Notification Portal (CPNP).
Picture of Marta Pinto

Marta Pinto

Regulatory Affairs Associate


According to the European Regulation on Cosmetic Products (Regulation (EC) No 1223/2009), before making available a cosmetic product on the market the Responsible Person (RP) shall notify the product in the Cosmetic Products Notification Portal (CPNP).

The CPNP is a free of charge online notification system created for the implementation of the European Cosmetics Regulation. After notification on the CPNP, there is no need for any further notification at national level within the EU.

The use of CPNP is mandatory since 2013. To access the Portal, the user needs a use login, a password, an organization, a role and a profile. The CPNP is relatively easy to use, but there are two user manuals issued by the European Commission, being one specific for cosmetics containing nanomaterials.

The RP or, under certain circumstances, the distributor needs to submit the following information on the CPNP:

  • Name/names (enabling its specific identification) and category of cosmetic product;
  • Name and address of the RP where the PIF is made readily accessible
  • Country of origin (for imported products)
  • Member State in which the cosmetic product is to be placed on the market
  • Contact details of a physical person to contact in case of necessity
  • Presence of nanomaterials, and:
    • their identification, including chemical name (IUPAC) and other descriptors as specified in Regulation:
    • reasonably foreseeable exposure conditions.
  • Name and the CAS or EC number of substances classified as CMR (carcinogenic, mutagenic or toxic to reproduction);
  • Frame formulation (allowing for prompt and appropriate medical treatment in the event of difficulties).

The original labelling, and, where reasonably legible, a photograph of the corresponding packaging must also be notified by the RP.

Part of the information submitted to the CPNP is made electronically available to competent authorities (for market surveillance, market analysis, evaluation and consumer information) and to poison centers or similar bodies established by EU countries (for the purposes of medical treatment).

Competent authorities, EU poison centers, RP and distributors can access the CPNP, but the portal is not accessible to the public.

The notification of cosmetic products containing nanomaterials must be done 6 months prior to placing them on the EU market.

All notifications made in the CPNP remain in the system and it is not possible to dele them. Nevertheless, the RP can create an update version and indicate in the correspondent field that the “product is no longer manufactured”.

Bare in mind that the fact that a cosmetic product has been successfully notified through the CPNP does not necessarily mean that the product fulfills all the requirements of the EU Cosmetic Regulation and is safe.

If you need any information regarding this or other subjects, fell free to contact us at


  1. Regulation (EC) No 1223/2009 of the European Parliament and of the Council of 30 November 2009 on cosmetic products.
  2. Guide to Using CPNP (Cosmetic Products Notification Portal) For Responsible Persons and Distributors. European Commission. 2017


medical devices

Safety Reporting in Clinical Investigations: a Gap Analysis of Guidance Documents 

Safety reporting in clinical investigations of medical devices shall be performed in line with Article 80(2) of the EU MDR. On May 2020, it was published the MDCG 2020-10/1, outlining the procedures for safety reporting in clinical investigations of medical devices under the EU MDR. However, on October 2022 the Medical Device Coordination Group (MDCG) published an updated version of the MDCG 2020-10/1, the MDCG 2020-10/1 Rev 1. This article highlights the updates included in the new revision, analysing the gaps between both documents.

Read More »
medical devices

Roles and Responsibilities of an Authorised Representative under EU MDR and IVDR 

If a medical device manufacturer is not established in a Member State, the devices can only be placed on the Union market if the manufacturer designates an authorised representative. The authorised representative plays a pivotal role in ensuring the compliance of the devices with EU regulation, serving as point of contact. The obligations and responsibilities of authorised representative are outlined on Article 11 of both MDR and IVDR, but clarification of relevant requirements is described in MDCG 2022-16 of October 2022.

Read More »
medical devices

Understanding the ISO Standards Lifecycle

ISO Standards cover a huge range of activities, representing the distilled wisdom of people with expertise in their subject matter and providing the regulators with a sound basis to develop better legislation. ISO Standards are diverse, addressing from the shoe size we wear to the quality of air we breathe. The medical device sector is no exception. ISO has many International Standards and guidance documents aimed at helping the sector ensure safe and effective medical devices while meeting the multitude of national, regional and international regulatory requirements. But how exactly is a Standard developed, reviewed and withdraw?

Read More »
medical devices

Amendments to the Transitional Provisions of the European Union MDR and IVDR

The proposed amendments aim to maintain patients’ access to a wide range of medical devices while ensuring the transition to the new framework. The ammendments proposal aims to extend the current transition period (Article 120 of the MDR), and it also deletes the ‘sell-off’ deadlines of both MDR and IVDR. The extension is staggered depending on the risk class of the device – until December 2027 for high-risk devices and December 2028 for medium and lower-risk devices.

Read More »
medical devices

EU MDR – Proposal for Extension of Transition Period

The transition to MDR has been slower than anticipated by the European Commission. Insufficient capacity of notified bodies and the low level of preparedness of manufacturers led to a proposal for extension of current MDR transition period with deadlines depending on the risk class of the devices.

Read More »
medical devices

MDCG 2022-18 – EU MDR Article 97

EU MDR Article 97 may be a temporary solution to avoid disruption of supply of Medical Devices on the EU Market. The MDCG 2022-18 presents a uniform approach for application of MDR Article 97 on non-compliant legacy devices under the conditions set by the competent authorities, while limiting the impact on the supply of safe and effective devices.

Read More »
cosmetic products

EU to set Labelling Requirements for 56 additional Fragrance Allergens in Cosmetic Products

World Trade Organization (WTO) has been notified by the European Commission of a draft amendment to Regulation (EC) No 1223/2009 as regards labelling of fragrance allergens in Cosmetic Products. The proposed date of adoption of the new regulation is expected to be in the first half of 2023 and the propose date of entry in force 20 days from the publication in the Official Journal of the European Union.

Read More »
cosmetic products

New Amendments to the European Cosmetics Regulation – CMR Substances

The European Commission published the Commission Regulation (EU) 2022/1531, which amends Regulation (EC) No 1223/2009 in regards to the use in cosmetic products of certain substances classified as CMR. This amendment introduces new entries to Annex II and Annex III and revises an entry to Annex V to Regulation (EC) No 1223/2009.

Read More »